Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alnylam Pharmaceuticals, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALNY
Nasdaq
8731
https://www.alnylam.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alnylam Pharmaceuticals, Inc.
Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22
- Jan 9th, 2023 6:22 pm
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
- Jan 8th, 2023 11:00 pm
3 Growth Stocks That Could Rocket Higher in 2023
- Jan 6th, 2023 10:39 am
Alnylam Announces Updates to its Board of Directors
- Jan 5th, 2023 9:00 pm
VERA Dips Despite Positive Data From IgA Nephropathy Study
- Jan 4th, 2023 5:20 pm
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2023 9:00 pm
The Petri Dish: Third Harmonic axes lead program; bluebird moves forward with 3rd drug
- Dec 22nd, 2022 10:41 am
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
- Dec 21st, 2022 1:00 pm
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
- Dec 15th, 2022 1:00 pm
Is There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 44% Undervaluation?
- Dec 13th, 2022 1:29 pm
Clovis (CLVS) Down 18.1% Since Last Earnings Report: Can It Rebound?
- Dec 9th, 2022 4:30 pm
Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy
- Dec 9th, 2022 4:21 pm
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
- Dec 8th, 2022 9:00 pm
Alnylam to Webcast Virtual R&D Day
- Dec 8th, 2022 12:00 pm
Why Is Intercept (ICPT) Down 3.9% Since Last Earnings Report?
- Dec 1st, 2022 4:31 pm
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
- Dec 1st, 2022 12:00 pm
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
- Nov 9th, 2022 1:00 pm
Investors ignore increasing losses at Alnylam Pharmaceuticals (NASDAQ:ALNY) as stock jumps 7.3% this past week
- Nov 2nd, 2022 3:45 pm
Top 10 Stock Picks of Eli Casdin’s Casdin Capital
- Oct 31st, 2022 12:49 pm
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
- Oct 27th, 2022 6:00 pm
Scroll